CNS Pharmaceuticals Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Rami Levin

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	1.4yrs

Actualizaciones recientes de la dirección

Recent updates

Seeking Alpha • Aug 15

CNS Pharmaceuticals reports Q2 results

CNS Pharmaceuticals press release (NASDAQ:CNSP): Q2 Net Loss of $3.6M As of June 30, 2022, the company had cash of approximately $9M and working capital of approximately $10.5M. The company's current expectation is that the cash on hand and the proceeds from the offering during January is sufficient to fund our operations into 2023.

Artículo de análisis • Dec 04

Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

CEO

Rami Levin (57 yo)

less than a year

Permanencia

Mr. Rami Levin, M.B.A. Director of CNS Pharmaceuticals, Inc. from December 2025 and serves as its President & CEO since January 01, 2026. Mr. Levin served as President at Saniona AB (publ) since January 7,...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Christopher Downs	Senior Vice President of Finance	less than a year	US$594.00k	0.00021% $ 14.2
Rami Levin	President	less than a year	sin datos	sin datos
Steve O'Loughlin	Chief Financial Officer	less than a year	sin datos	sin datos
Eric Faulkner	Chief Technology Officer	less than a year	sin datos	sin datos
Dylan Wenke	Chief Business Officer	less than a year	sin datos	sin datos
E. Kelley	Chief Medical Officer	less than a year	sin datos	sin datos

0.3yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CNSP no se considera experimentado ( 0.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Rami Levin	President	less than a year	sin datos	sin datos
Faith Charles	Independent Chairman of Board	3.5yrs	US$81.50k	0.49% $ 32.9k
Roger Stupp	Scientific Advisory Panel	less than a year	sin datos	sin datos
Jeffry Keyes	Independent Director	8yrs	US$61.00k	0% $ 0
Bettina Cockroft	Independent Director	3.1yrs	US$54.00k	0% $ 0
Amy Mahery	Independent Director	2.3yrs	US$59.28k	0% $ 0
Timothy Cloughesy	Scientific Advisory Panel	1.4yrs	sin datos	sin datos
Mark Gilbert	Scientific Advisory Panel	1.4yrs	sin datos	sin datos
Michal Fisher	Independent Director	less than a year	sin datos	sin datos

1.4yrs

Permanencia media

55yo

Promedio de edad

Junta con experiencia: La junta directiva de CNSP no se considera experimentada (1.4 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/06/17 10:33
Precio de las acciones al final del día	2026/06/17 00:00
Beneficios	2026/03/31
Ingresos anuales	2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

CNS Pharmaceuticals, Inc. está cubierta por 3 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Bruce Jackson	Benchmark Company
Robert LeBoyer	Ladenburg Thalmann & Company
Jason McCarthy	Maxim Group

CNS Pharmaceuticals Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

High number of new and inexperienced directors

CNS Pharmaceuticals, Inc., Annual General Meeting, Nov 17, 2025

CNS Pharmaceuticals, Inc., Annual General Meeting, Apr 30, 2024

CNS Pharmaceuticals, Inc. Appoints Amy Mahery to its Board of Directors

CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

Bettina M. Cockroft Joins CNS Pharmaceuticals, Inc.'s Board of Directors

Recent updates

CNS Pharmaceuticals, Inc. announced that it expects to receive $22.515858 million in funding from ADAR1 Capital Management, LLC, Ikarian Capital, LLC, Stonepine Capital Management LLC, Nazare Partners

New major risk - Share price stability

New minor risk - Share price stability

High number of new and inexperienced directors

CNS Pharmaceuticals, Inc., Annual General Meeting, Nov 17, 2025

New major risk - Financial position

CNS Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.996373 million.

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $14 million.

New major risk - Financial position

No longer forecast to breakeven

New minor risk - Profitability

New major risk - Revenue and earnings growth

New major risk - Share price stability

Forecast to breakeven in 2027

CNS Pharmaceuticals Receives Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3 million.

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

CNS Pharmaceuticals, Inc. announced that it expects to receive funding from Cortice Biosciences Incorporated

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5.2 million.

The Nasdaq Hearings Panel Grants the Requested Extension to CNS Pharmaceuticals Until August 12, 2024

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.98075 million.

CNS Pharmaceuticals, Inc. announced a financing transaction

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3725 million.

New major risk - Share price stability

CNS Pharmaceuticals, Inc., Annual General Meeting, Apr 30, 2024

CNS Pharmaceuticals Receives Non-Compliance Letter Form Nasdaq

CNS Pharmaceuticals Provides Non-Compliance Update

CNS Pharmaceuticals, Inc. Appoints Amy Mahery to its Board of Directors

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

CNS Pharmaceuticals, Inc. Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

New major risk - Negative shareholders equity

CNS Pharmaceuticals, Inc. Opens 46 Clinical Trial Sites Across the U.S., Italy, France, Spain, and Switzerland

Cns Pharmaceuticals, Inc. Announces Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (Gbm)

CNS Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement Pursuant to Nasdaq’s Listing Rule 5550(b)(1)

CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

CNS Pharmaceuticals, Inc. Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

CNS Pharmaceuticals, Inc. Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme

Bettina M. Cockroft Joins CNS Pharmaceuticals, Inc.'s Board of Directors

CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Investigator-Initiated Phase 1B/2 Trial to Be Conducted At the Pomeranian Medical University in Poland

Cns Pharmaceuticals, Inc. Appoints Faith Charles as Independent Member and as Chairperson of the Board of Directors

CNS Pharmaceuticals, Inc Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)

CNS Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Insufficient new directors

CNS Pharmaceuticals, Inc. Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Provides A Clinical Update of Its Anti-Cancer Drug Candidates Currently in Development for the Treatment of Primary and Metastatic Brain and CNS Cancer

CNS Pharmaceuticals reports Q2 results

CNS Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2022

CNS Pharmaceuticals Inc. Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Price target increased to US$10.00

Insufficient new directors

CNS Pharmaceuticals, Inc. Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme

CNS Pharmaceuticals, Inc. announced that it expects to receive $11.500001 million in funding

Insufficient new directors

Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation

CNS Pharmaceuticals, Inc. Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme

CEO

Equipo directivo

Miembros de la Junta

Análisis de la empresa y estado de los datos financieros

Fuentes de datos

Modelo de análisis y copo de nieve

Métricas industriales y sectoriales

Fuentes analistas